Claims for Patent: 4,369,184

Summary for Patent: 4,369,184

Title:	1-(Cyclohexyl)-4-aryl-4-piperidinecarboxylic acid derivatives
Abstract:	Novel 1-(cyclohexyl)-4-aryl-4-piperidinecarboxylic acid derivatives, bearing in the 4-position of the cyclohexyl ring a cyano group and an aryl moiety, said compounds displaying useful antihistaminic properties.
Inventor(s):	Stokbroekx; Raymond A. (Beerse, BE), Luyckx; Marcel G. M. (Geel, BE), Willems; Joannes J. M. (Turnhout, BE)
Assignee:	Janssen Pharmaceutica N.V. (Beerse, BE)
Application Number:	06/191,631
Patent Claims:	1. A chemical compound having the formula ##STR18## the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof, wherein: R.sup.1 is a member selected from the group consisting of hydrogen and lower alkyl; R is a member selected from the group consisting of hydroxy, lower alkyloxy, aryllower alkyloxy, aryloxylower alkyloxy, lower alkyloxylower alkyloxy, aminolower alkyloxy, mono- and di(lower alkyl)amino lower alkyloxy, (1-pyrrolidinyl)-, (1-piperidinyl)- and (4-morpholinyl)lower alkyloxy, amino, aryllower alkyl amino, mono- and di(lower alkyl)amino, 1-pyrrolidinyl, 1-piperidinyl and 4-morpholinyl; and Ar.sup.1 and Ar.sup.2 are each independently selected from the group consisting of aryl, thienyl and pyridinyl; wherein aryl, as used in the definitions of R, Ar.sup.1 and Ar.sup.2, is a membere selected from the group consising of phenyl and substituted phenyl, said substituted phenyl having from 1 to 3 substituents each independently selected from the group consisting of lower alkyl, lower alkyloxy, halo, nitro, amino, cyano, carboxyl, lower alkyloxy carbonyl, mono- and di(lower alkyl)aminocarbonyl and trifluoromethyl. 2. A chemical compound selected from the group consisting of 1-[4-cyano-4-(4-fluorophenyl)cyclohexyl]-3-methyl-4-phenyl-4-piperidinecar boxylic acid, the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof. 3. An antihistaminic pharmaceutical composition comprising an inert carrier material and as an active ingredient an effective antihistaminic amount of a chemical compound selected from the group consisting of a 1-(cyclohexyl)-4-aryl-4-piperidinecarboxylic acid derivative having the formula ##STR19## the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof, wherein: R.sup.1 is a member selected from the group consisting of hydrogen and lower alkyl; R is a member selected from the group consisting of hydroxy, lower alkyloxy, aryllower alkyloxy, aryloxylower alkyloxy, lower alkyloxylower alkyloxy, aminolower alkyloxy, mono- and di(lower alkyl)aminolower alkyloxy, (1-pyrrolidinyl)-, 1-(piperidinyl)- and (4-morpholinyl)lower alkyloxy, amino, aryllower alkylamino, mono- and di(lower alkyl)amino, 1-pyrrolidinyl, 1-piperidinyl and 4-morpholinyl; and Ar.sup.1 and Ar.sup.2 are each independently selected from the group consisting of aryl, thienyl and pyridinyl; wherein aryl, as used in the definitions of R, Ar.sup.1 and Ar.sup.2, is a member selected from the group consisting of phenyl and substituted phenyl, said substituted phenyl having from 1 to 3 substituents each independently selected from the group consisting of lower alkyl, lower alkyloxy, halo, nitro, amino, cyano, carboxyl, lower alkyloxy carbonyl, mono- and di(lower alkyl)aminocarbonyl and trifluoromethyl. 4. An antihistaminic pharmaceutical composition comprising an inert carrier material and as an active ingredient an effective antihistaminic amount of a chemical compound selected from the group consisting of 1-[4-cyano-4-(4-fluorophenyl)cyclohexyl]-3-methyl-4-phenyl-4-piperidinecar boxylic acid, the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof. 5. A method to prevent the release of histamine in warm-blooded animals which comprises the systemic administration to said animals of an effective antihistaminic amount of a chemical compound selected from the group consisting of a 1-(cyclohexyl)-4-aryl-4-piperidinecarboxylic acid derivative having the formula ##STR20## the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof, wherein: R.sup.1 is a member selected from the group consisting of hydrogen and lower alkyl; R is a member selected from the group consisting of hydroxy, lower alkyloxy, aryllower alkyloxy, aryloxylower alkyloxy, lower alkyloxylower alkyloxy, aminolower alkyloxy, mono- and di(lower alkyl)aminolower alkyloxy, (1-pyrrolidinyl)-, (1-piperidinyl)- and (4-morpholinyl)lower alkyloxy, amino, aryllower alkylamino, mono- and di(lower alkyl)amino, 1-pyrrolidinyl, 1-piperidinyl and 4-morpholinyl; and Ar.sup.1 and Ar.sup.2 are each independently selected from the group consisting of aryl, thienyl and pyridinyl; wherein aryl, as used in the definitions of R, Ar.sup.1 and Ar.sup.2, is a member selected from the group consisting of phenyl and substituted phenyl, said substituted phenyl having from 1 to 3 substituents each independently selected from the group consisting of lower alkyl, lower alkyloxy, halo, nitro, amino, cyano, carboxyl, lower alkyloxycarbonyl, mono- and di(lower alkyl)aminocarbonyl and trifluoromethyl. 6. A method to prevent the release of histamine in warm-blooded animals which comprises the systemic administration to said animals of an effective antihistaminic amount of a chemical compound selected from the group consisting of 1-[4-cyano-4-(4-fluorophenyl)cyclohexyl]-3-methyl-4-phenyl-4-piperidinecar boxylic acid, the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof. 7. A chemical compound having the formula ##STR21## the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof, wherein: R.sup.1 is a member selected from the group consisting of hydrogen and lower alkyl; R is a member selected from the group consisting of hydroxy, lower alkyloxy, aryllower alkyloxy, aryloxylower alkyloxy, lower alkyloxylower alkyloxy, aminolower alkyloxy, mono- and di(lower alkyl)amino lower alkyloxy, (1-pyrrolidinyl)-, (1-piperidinyl)- and (4-morpholinyl)lower alkyloxy, amino, aryllower alkylamino, mono- and di(lower alkyl)amino, 1-pyrrolidinyl, 1-piperidinyl and 4-morpholinyl; and Ar.sup.1 and Ar.sup.2 are each independently selected from the group consisting of aryl, thienyl and pyridinyl; wherein aryl, as used in the definitions of R, Ar.sup.1 and Ar.sup.2, is a member selected from the group consisting of phenyl and substituted phenyl, said substituted phenyl having from 1 to 3 substituents each independently selected from the group consisting of lower alkyl, lower alkyloxy, halo, nitro, amino, cyano, carboxyl, lower alkyloxycarbonyl, mono- and di(lower alkyl)aminocarbonyl and trifluoromethyl.